arrow_back Back to App

Safe Medicine Act: Ending Foreign Pharmaceutical Dependence

This act aims to boost domestic generic drug production to reduce reliance on foreign suppliers, particularly China. It mandates warnings on potentially contaminated drugs and strengthens quality control. This means citizens can expect safer and more readily available medications, produced within the country.
Key points
More generic drugs will be produced in the U.S., reducing the risk of shortages.
Imported drugs from countries with quality control issues will require special warnings on their packaging.
The government will prioritize purchasing drugs and ingredients from U.S. or allied manufacturers, supporting domestic industry.
Enhanced oversight of drug ingredients to prevent contamination and counterfeiting.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_5575
Sponsor: Rep. Posey, Bill [R-FL-8]
Process start date: 2023-09-19
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Safe Medicine Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_5575.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-09-19.

What are the main provisions?

Key points include:

  • More generic drugs will be produced in the U.S., reducing the risk of shortages.
  • Imported drugs from countries with quality control issues will require special warnings on their packaging.
  • The government will prioritize purchasing drugs and ingredients from U.S. or allied manufacturers, supporting domestic industry.
  • Enhanced oversight of drug ingredients to prevent contamination and counterfeiting.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Posey, Bill [R-FL-8].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Security Economy